Biocytogen Secures U.S. Patent for Key Technology of the Fully Human Antibody Mouse (RenMab) Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) is pleased to announce that the company has been granted a patent from the United States Patent…
Read more
Nov 2023 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Catalog Number Product 112766 B-hTGFBR2/hPDGFRA mice 113092 B-hCD3E/hCD28/hCD19 mice 113093 B-hCD3E/hCD28/hMUC1 mice 113040 B-hPD-1/hPD-L1/HLA-A2.1 mice Humanized Cytokine Mice Catalog…
Read more
SITC 2023 Highlights: Biocytogen’s Novel Assets and Products
The Biocytogen team concluded a successful SITC 2023 event, after presenting 9 drug asset posters, 7 genetically engineered mouse model posters, and connecting with current…
Read more
Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti- CD40 mAb) Phase I Trial at ESMO 2023
Beijing, China, Oct 16, 2023 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), will attend and present…
Read more
Biocytogen Officially Launches RenMice® Series
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen's Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen…
Read more
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Beijing, China, September 7, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody…
Read more
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D
Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to…
Read more
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today…
Read more
Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
BEIJING, China--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is…
Read more
Biocytogen Announces Grand Opening of Waltham, MA Facility
State-of-the-Art Facility Signifies Growth of Business in North America and Europe August 16, 2023, Waltham, MA & Beijing, China - Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”),…
Read more